IQ EQ FUND MANAGEMENT IRELAND Ltd Purchases 4,411 Shares of Hologic, Inc. (NASDAQ:HOLX)

IQ EQ FUND MANAGEMENT IRELAND Ltd increased its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 14.3% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 35,221 shares of the medical equipment provider’s stock after buying an additional 4,411 shares during the quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in Hologic were worth $2,869,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Price T Rowe Associates Inc. MD boosted its holdings in Hologic by 77.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock valued at $490,931,000 after purchasing an additional 2,753,016 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in Hologic by 21.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,535,258 shares of the medical equipment provider’s stock valued at $188,243,000 after purchasing an additional 450,190 shares during the period. Black Creek Investment Management Inc. boosted its holdings in Hologic by 60.9% in the 2nd quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock valued at $173,669,000 after purchasing an additional 885,524 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Hologic by 5.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,326,992 shares of the medical equipment provider’s stock valued at $172,780,000 after purchasing an additional 124,739 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in Hologic by 4.0% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,271,603 shares of the medical equipment provider’s stock valued at $168,666,000 after purchasing an additional 87,176 shares during the period. 94.73% of the stock is owned by institutional investors.

Hologic Trading Up 0.3 %

Shares of Hologic stock opened at $81.94 on Thursday. The stock has a market capitalization of $19.12 billion, a P/E ratio of 41.81, a price-to-earnings-growth ratio of 2.89 and a beta of 0.98. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51. The company has a 50-day simple moving average of $81.04 and a 200 day simple moving average of $77.67. Hologic, Inc. has a 12-month low of $64.02 and a 12-month high of $84.67.

Hologic (NASDAQ:HOLX) last announced its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1 billion. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The firm’s revenue for the quarter was up 2.7% on a year-over-year basis. During the same quarter last year, the company posted $0.93 EPS. Research analysts expect that Hologic, Inc. will post 4.09 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have weighed in on HOLX. Citigroup downgraded shares of Hologic from a “buy” rating to a “neutral” rating and reduced their price target for the company from $95.00 to $85.00 in a report on Tuesday, October 1st. Mizuho increased their price target on shares of Hologic from $85.00 to $90.00 and gave the company an “outperform” rating in a report on Friday, October 4th. Stephens restated an “overweight” rating and issued a $92.00 price objective on shares of Hologic in a research note on Tuesday, July 30th. Royal Bank of Canada restated a “sector perform” rating and issued a $82.00 price objective on shares of Hologic in a research note on Friday, August 16th. Finally, Needham & Company LLC restated a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research note on Tuesday. Five research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $87.50.

Insider Buying and Selling

In related news, insider Benjamin Jordan Cohn sold 5,093 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $81.99, for a total transaction of $417,575.07. Following the completion of the sale, the insider now owns 10,476 shares in the company, valued at $858,927.24. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other Hologic news, insider Brandon Schnittker sold 476 shares of the firm’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total value of $39,560.36. Following the completion of the sale, the insider now owns 3,735 shares in the company, valued at approximately $310,415.85. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Benjamin Jordan Cohn sold 5,093 shares of the firm’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $81.99, for a total transaction of $417,575.07. Following the completion of the sale, the insider now owns 10,476 shares of the company’s stock, valued at $858,927.24. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 1.75% of the stock is currently owned by corporate insiders.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.